NASDAQ:CBAY

CymaBay Therapeutics Competitors

$4.17
+0.02 (+0.48 %)
(As of 04/20/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.03
Now: $4.17
$4.23
50-Day Range
$4.19
MA: $4.65
$5.18
52-Week Range
$1.50
Now: $4.17
$9.06
Volume805,504 shs
Average Volume1.12 million shs
Market Capitalization$287.50 million
P/E RatioN/A
Dividend YieldN/A
Beta1.45

Competitors

CymaBay Therapeutics (NASDAQ:CBAY) Vs. PTGX, YMAB, PHAT, KRON, OMER, and STOK

Should you be buying CBAY stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to CymaBay Therapeutics, including Protagonist Therapeutics (PTGX), Y-mAbs Therapeutics (YMAB), Phathom Pharmaceuticals (PHAT), Kronos Bio (KRON), Omeros (OMER), and Stoke Therapeutics (STOK).

Protagonist Therapeutics (NASDAQ:PTGX) and CymaBay Therapeutics (NASDAQ:CBAY) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, risk, analyst recommendations, valuation, institutional ownership and dividends.

Valuation and Earnings

This table compares Protagonist Therapeutics and CymaBay Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagonist Therapeutics$230,000.005,085.46$-77,190,000.00($2.98)-8.93
CymaBay TherapeuticsN/AN/A$-102,810,000.00($1.46)-2.86

Protagonist Therapeutics has higher revenue and earnings than CymaBay Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than CymaBay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings for Protagonist Therapeutics and CymaBay Therapeutics, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Protagonist Therapeutics00703.00
CymaBay Therapeutics001113.08

Protagonist Therapeutics presently has a consensus price target of $38.00, indicating a potential upside of 42.75%. CymaBay Therapeutics has a consensus price target of $11.7692, indicating a potential upside of 182.91%. Given CymaBay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CymaBay Therapeutics is more favorable than Protagonist Therapeutics.

Risk and Volatility

Protagonist Therapeutics has a beta of 1.56, indicating that its stock price is 56% more volatile than the S&P 500. Comparatively, CymaBay Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500.

Insider & Institutional Ownership

97.5% of Protagonist Therapeutics shares are owned by institutional investors. Comparatively, 84.3% of CymaBay Therapeutics shares are owned by institutional investors. 14.2% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 4.0% of CymaBay Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Protagonist Therapeutics and CymaBay Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Protagonist Therapeutics-252.03%-54.00%-35.38%
CymaBay TherapeuticsN/A-34.86%-32.23%

Summary

CymaBay Therapeutics beats Protagonist Therapeutics on 9 of the 14 factors compared between the two stocks.

CymaBay Therapeutics (NASDAQ:CBAY) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Valuation & Earnings

This table compares CymaBay Therapeutics and Y-mAbs Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CymaBay TherapeuticsN/AN/A$-102,810,000.00($1.46)-2.86
Y-mAbs TherapeuticsN/AN/A$-81,030,000.00($2.30)-11.35

Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than CymaBay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of recent ratings and price targets for CymaBay Therapeutics and Y-mAbs Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CymaBay Therapeutics001113.08
Y-mAbs Therapeutics02602.75

CymaBay Therapeutics presently has a consensus price target of $11.7692, suggesting a potential upside of 182.91%. Y-mAbs Therapeutics has a consensus price target of $58.1429, suggesting a potential upside of 122.68%. Given CymaBay Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe CymaBay Therapeutics is more favorable than Y-mAbs Therapeutics.

Risk and Volatility

CymaBay Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500.

Insider and Institutional Ownership

84.3% of CymaBay Therapeutics shares are owned by institutional investors. Comparatively, 53.2% of Y-mAbs Therapeutics shares are owned by institutional investors. 4.0% of CymaBay Therapeutics shares are owned by insiders. Comparatively, 38.4% of Y-mAbs Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares CymaBay Therapeutics and Y-mAbs Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CymaBay TherapeuticsN/A-34.86%-32.23%
Y-mAbs TherapeuticsN/A-74.98%-66.70%

Summary

CymaBay Therapeutics beats Y-mAbs Therapeutics on 10 of the 12 factors compared between the two stocks.

CymaBay Therapeutics (NASDAQ:CBAY) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership and earnings.

Analyst Ratings

This is a breakdown of recent ratings and price targets for CymaBay Therapeutics and Phathom Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CymaBay Therapeutics001113.08
Phathom Pharmaceuticals10402.60

CymaBay Therapeutics presently has a consensus price target of $11.7692, suggesting a potential upside of 182.91%. Phathom Pharmaceuticals has a consensus price target of $53.00, suggesting a potential upside of 49.72%. Given CymaBay Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe CymaBay Therapeutics is more favorable than Phathom Pharmaceuticals.

Valuation & Earnings

This table compares CymaBay Therapeutics and Phathom Pharmaceuticals' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CymaBay TherapeuticsN/AN/A$-102,810,000.00($1.46)-2.86
Phathom PharmaceuticalsN/AN/A$-255,130,000.00($13.98)-2.53

CymaBay Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares CymaBay Therapeutics and Phathom Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CymaBay TherapeuticsN/A-34.86%-32.23%
Phathom PharmaceuticalsN/A-88.73%-69.04%

Risk and Volatility

CymaBay Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500.

Insider and Institutional Ownership

84.3% of CymaBay Therapeutics shares are owned by institutional investors. Comparatively, 73.8% of Phathom Pharmaceuticals shares are owned by institutional investors. 4.0% of CymaBay Therapeutics shares are owned by insiders. Comparatively, 39.8% of Phathom Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

CymaBay Therapeutics beats Phathom Pharmaceuticals on 10 of the 12 factors compared between the two stocks.

Kronos Bio (NASDAQ:KRON) and CymaBay Therapeutics (NASDAQ:CBAY) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

Valuation and Earnings

This table compares Kronos Bio and CymaBay Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kronos BioN/AN/AN/AN/AN/A
CymaBay TherapeuticsN/AN/A$-102,810,000.00($1.46)-2.86

Analyst Ratings

This is a summary of current ratings and recommmendations for Kronos Bio and CymaBay Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Kronos Bio00403.00
CymaBay Therapeutics001113.08

Kronos Bio presently has a consensus price target of $43.6667, suggesting a potential upside of 117.46%. CymaBay Therapeutics has a consensus price target of $11.7692, suggesting a potential upside of 182.91%. Given CymaBay Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe CymaBay Therapeutics is more favorable than Kronos Bio.

Profitability

This table compares Kronos Bio and CymaBay Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Kronos BioN/AN/AN/A
CymaBay TherapeuticsN/A-34.86%-32.23%

Institutional and Insider Ownership

84.3% of CymaBay Therapeutics shares are owned by institutional investors. 4.0% of CymaBay Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

CymaBay Therapeutics beats Kronos Bio on 6 of the 8 factors compared between the two stocks.

CymaBay Therapeutics (NASDAQ:CBAY) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, dividends, analyst recommendations, valuation and risk.

Earnings and Valuation

This table compares CymaBay Therapeutics and Omeros' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CymaBay TherapeuticsN/AN/A$-102,810,000.00($1.46)-2.86
Omeros$111.81 million10.28$-84,490,000.00($0.96)-19.32

Omeros has higher revenue and earnings than CymaBay Therapeutics. Omeros is trading at a lower price-to-earnings ratio than CymaBay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

CymaBay Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the S&P 500. Comparatively, Omeros has a beta of 1.65, suggesting that its stock price is 65% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for CymaBay Therapeutics and Omeros, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CymaBay Therapeutics001113.08
Omeros02402.67

CymaBay Therapeutics currently has a consensus target price of $11.7692, indicating a potential upside of 182.91%. Omeros has a consensus target price of $23.40, indicating a potential upside of 26.15%. Given CymaBay Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe CymaBay Therapeutics is more favorable than Omeros.

Profitability

This table compares CymaBay Therapeutics and Omeros' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CymaBay TherapeuticsN/A-34.86%-32.23%
Omeros-134.59%N/A-59.49%

Institutional and Insider Ownership

84.3% of CymaBay Therapeutics shares are held by institutional investors. Comparatively, 56.6% of Omeros shares are held by institutional investors. 4.0% of CymaBay Therapeutics shares are held by company insiders. Comparatively, 11.3% of Omeros shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

CymaBay Therapeutics beats Omeros on 8 of the 14 factors compared between the two stocks.

CymaBay Therapeutics (NASDAQ:CBAY) and Stoke Therapeutics (NASDAQ:STOK) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their risk, earnings, dividends, institutional ownership, valuation, profitability and analyst recommendations.

Profitability

This table compares CymaBay Therapeutics and Stoke Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
CymaBay TherapeuticsN/A-34.86%-32.23%
Stoke TherapeuticsN/A-22.93%-22.26%

Analyst Recommendations

This is a breakdown of current ratings and target prices for CymaBay Therapeutics and Stoke Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
CymaBay Therapeutics001113.08
Stoke Therapeutics02602.75

CymaBay Therapeutics currently has a consensus price target of $11.7692, indicating a potential upside of 182.91%. Stoke Therapeutics has a consensus price target of $64.3333, indicating a potential upside of 106.46%. Given CymaBay Therapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe CymaBay Therapeutics is more favorable than Stoke Therapeutics.

Institutional and Insider Ownership

84.3% of CymaBay Therapeutics shares are held by institutional investors. 4.0% of CymaBay Therapeutics shares are held by insiders. Comparatively, 54.6% of Stoke Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares CymaBay Therapeutics and Stoke Therapeutics' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CymaBay TherapeuticsN/AN/A$-102,810,000.00($1.46)-2.86
Stoke TherapeuticsN/AN/A$-32,330,000.00($1.80)-17.31

Stoke Therapeutics is trading at a lower price-to-earnings ratio than CymaBay Therapeutics, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

CymaBay Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the S&P 500. Comparatively, Stoke Therapeutics has a beta of 0.63, meaning that its share price is 37% less volatile than the S&P 500.

Summary

CymaBay Therapeutics beats Stoke Therapeutics on 8 of the 12 factors compared between the two stocks.

Ad PulseStocks
Rare EV Stock Alert
The world is moving towards EV and this stock is seeing the upwards trend.

CymaBay Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$26.62+2.0%$1.15 billion$230,000.00-12.38
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$26.11+2.5%$1.14 billionN/A-8.79Increase in Short Interest
News Coverage
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$35.40+2.3%$1.13 billionN/A-2.53
Kronos Bio logo
KRON
Kronos Bio
1.7$20.08+0.1%$1.13 billionN/A0.00
Omeros logo
OMER
Omeros
1.4$18.55+2.5%$1.12 billion$111.81 million-7.79News Coverage
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$31.16+2.0%$1.12 billionN/A-17.31
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$16.10+3.9%$1.10 billionN/A-6.79Upcoming Earnings
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$15.90+0.4%$1.10 billion$42.12 million-11.78
NKTX
Nkarta
1.8$31.25+4.0%$1.07 billionN/A0.00
Zogenix logo
ZGNX
Zogenix
1.7$18.80+0.6%$1.05 billion$3.65 million-1.98
MannKind logo
MNKD
MannKind
1.4$4.23+1.7%$1.04 billion$63.04 million-20.14Increase in Short Interest
News Coverage
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$21.60+0.3%$1.03 billionN/A-7.97
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$51.10+2.4%$1.03 billion$122.47 million-28.08
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$25.97+2.3%$1.03 billionN/A0.00News Coverage
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$20.38+0.6%$1.02 billionN/A-6.70Increase in Short Interest
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
2.0$28.18+0.9%$1.02 billion$57.05 million0.00Analyst Report
News Coverage
Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$8.94+21.8%$1.01 billion$35.22 million-6.53Gap Up
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$24.85+0.7%$1.01 billion$800.40 million23.44
Arcturus Therapeutics logo
ARCT
Arcturus Therapeutics
1.6$36.64+0.7%$970.00 million$20.79 million-12.63
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$22.67+0.4%$951.21 millionN/A-7.82
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.23+4.3%$950.88 million$120,000.00-3.42Analyst Report
News Coverage
Akero Therapeutics logo
AKRO
Akero Therapeutics
1.7$27.87+2.8%$941.57 millionN/A-12.84
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$17.33+3.2%$920.14 millionN/A0.00
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$16.55+0.7%$908.31 million$227.19 million45.97Analyst Downgrade
Prothena logo
PRTA
Prothena
2.3$22.53+5.5%$901.34 million$810,000.00-8.80
Radius Health logo
RDUS
Radius Health
1.3$19.13+1.2%$886.30 million$173.32 million-7.84
Affimed logo
AFMD
Affimed
1.6$8.96+7.4%$880.65 million$23.96 million-15.19Earnings Announcement
Analyst Report
Analyst Revision
Ardelyx logo
ARDX
Ardelyx
1.6$8.07+9.2%$868.88 million$5.28 million-7.99Increase in Short Interest
Merus logo
MRUS
Merus
1.8$22.06+0.2%$842.61 million$31.13 million-7.19
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.7$17.14+0.9%$825.04 million$322.36 million122.43
Annexon logo
ANNX
Annexon
1.9$21.78+1.2%$821.16 millionN/A0.00
ESSA Pharma logo
EPIX
ESSA Pharma
1.6$24.17+2.9%$816.46 millionN/A-22.38
BioXcel Therapeutics logo
BTAI
BioXcel Therapeutics
1.6$34.04+2.6%$814.84 millionN/A-10.10News Coverage
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$22.81+2.0%$803.00 million$296.70 million46.55Analyst Revision
Epizyme logo
EPZM
Epizyme
1.8$7.74+0.1%$786.80 million$23.80 million-3.47Analyst Report
News Coverage
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.54+2.4%$775.42 million$148.36 million-7.15
ORIC Pharmaceuticals logo
ORIC
ORIC Pharmaceuticals
1.7$21.02+0.1%$771.33 millionN/A0.00Increase in Short Interest
Humanigen logo
HGEN
Humanigen
1.7$13.54+2.6%$742.87 millionN/A0.00Analyst Report
News Coverage
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.6$18.55+6.8%$709.73 million$6.83 million-19.12
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.6$4.88+0.8%$704.45 million$322.07 million-4.65Upcoming Earnings
Decrease in Short Interest
News Coverage
Karyopharm Therapeutics logo
KPTI
Karyopharm Therapeutics
1.7$9.44+2.2%$692.81 million$40.89 million-3.26News Coverage
ZIOPHARM Oncology logo
ZIOP
ZIOPHARM Oncology
1.3$3.17+0.9%$682.20 million$150,000.00-4.53News Coverage
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$26.02+3.4%$671.97 million$19.56 million-18.72
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
2.2$20.80+2.9%$666.59 million$252 million-2.13
Chimerix logo
CMRX
Chimerix
1.3$7.91+1.8%$665.73 million$12.52 million-13.88
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$2.61+1.1%$662.95 million$2.22 million-15.35News Coverage
Gap Down
Veru logo
VERU
Veru
1.4$8.88+2.4%$653.68 million$42.59 million-31.71Analyst Report
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$29.32+4.2%$648.83 million$13.80 million-14.16Analyst Report
News Coverage
Syndax Pharmaceuticals logo
SNDX
Syndax Pharmaceuticals
1.6$13.42+44.4%$647.33 million$1.52 million-7.14Increase in Short Interest
News Coverage
Gap Down
Kadmon logo
KDMN
Kadmon
1.8$3.83+3.1%$637.44 million$5.09 million-6.38
This page was last updated on 4/20/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.